Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to $194.9 million.

  • Standard Biotools' Cash & Current Investments fell 4698.26% to $194.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $194.9 million, marking a year-over-year decrease of 4698.26%. This contributed to the annual value of $292.9 million for FY2024, which is 15315.41% up from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Cash & Current Investments is $194.9 million, which was down 4698.26% from $237.1 million recorded in Q2 2025.
  • Standard Biotools' 5-year Cash & Current Investments high stood at $463.6 million for Q1 2024, and its period low was $29.5 million during Q4 2021.
  • Its 5-year average for Cash & Current Investments is $183.8 million, with a median of $166.8 million in 2022.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 5866.28% in 2021, then surged by 56572.67% in 2022.
  • Standard Biotools' Cash & Current Investments (Quarter) stood at $29.5 million in 2021, then surged by 466.05% to $166.8 million in 2022, then plummeted by 30.64% to $115.7 million in 2023, then skyrocketed by 153.15% to $292.9 million in 2024, then plummeted by 33.45% to $194.9 million in 2025.
  • Its Cash & Current Investments stands at $194.9 million for Q3 2025, versus $237.1 million for Q2 2025 and $258.1 million for Q1 2025.